Bank of New York Mellon’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Bank of New York Mellon’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-69,630	Closed	-$184K	–	4215
2020 Q1	$184K	Sell	69,630 -401	-0.6%	-$658	﹤0.01%	3763
2019 Q4	$83K	Buy	70,031 +15,588	+29%	+$24.9K	﹤0.01%	4045
2019 Q3	$94K	Sell	54,443 -17,000	-24%	-$51.7K	﹤0.01%	4032
2019 Q2	$339K	Buy	71,443 +37,755	+112%	+$211K	﹤0.01%	3764
2019 Q1	$218K	Buy	33,688 +14,261	+73%	+$74.7K	﹤0.01%	3859
2018 Q4	$98K	Buy	19,427 +2,905	+18%	+$20.3K	﹤0.01%	3962
2018 Q3	$141K	Buy	+16,522	New	+$183K	﹤0.01%	3988

Bank of New York Mellon's NTGN Position: Q2 2020 in Review

Bank of New York Mellon sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 69,630 shares — an estimated $184K sold.

Bank of New York Mellon first reported a position in NTGN in Q3 2018 and held it in 7 quarters. The position peaked at $339K in Q2 2019. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

Bank of New York Mellon reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Bank of New York Mellon sold 69,630 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $184K.
Bank of New York Mellon first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2018 and held it in 7 quarters.
Bank of New York Mellon's Neon Therapeutics, Inc. Common Stock position peaked at $339K in Q2 2019.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Bank of New York Mellon's 13F filing for Q2 2020, filed 12 Aug 2020.